This is exemplified by the enhanced response of cancer cells, with defects in the DNA repair genes BRCA1 or BRCA2, to inhibitors of the DDR signaling enzyme PARP1 (35,36) or the endonuclease APE2 (37,38), among other targets. This evidence concerns the gene BRCA2 and cancer.